Overview of Cydectin TriclaMox

Property	Description
Active Ingredients	Moxidectin, Triclabendazole
Form	Oral Solution (Drench)
Pharmacological Class	Anthelmintic, Endectocide, Flukicide
Common Use	Management of mixed parasitic infections (Nematodes and Flukes)
Origin	Semi-synthetic/Synthetic Combination

Definition and Pharmacological Classification

Cydectin TriclaMox is a specialized veterinary medicinal product primarily designated for use in sheep, and is often classified as a Prescription Only Medicine (POM-VPS) in many regions. Pharmacologically, it is a dual-active anthelmintic and a fluke and wormer combination dose, a status that is clinically recognized for addressing complex parasitic resistance challenges. The medicine's core identity lies in its ability to concurrently target two distinct groups of internal parasites, a strategy widely supported by veterinary research for comprehensive parasite control.

Composition, Origin, and Form

This specific formulation is defined by the combination of its two main active ingredients: Moxidectin and Triclabendazole. Moxidectin is classified as a semi-synthetic Macrocyclic Lactone, which acts as the endectocide, while Triclabendazole, a synthetic Benzimidazole derivative, serves as the potent flukicide. The unique combination of these two distinct chemical classes ensures a broad spectrum of antiparasitic activity. Cydectin TriclaMox is presented as an oral solution or oral drench for ease of oral use, utilizing a specialized base/vehicle designed for efficient administration to the target species.

General Purpose of the Dual-Active Formula

The general purpose of this medicine is to provide effective, concurrent control over two major parasitic groups: nematodes (roundworms) and trematodes (flukes), specifically addressing mixed nematode and trematode infections. The dual-active mechanism ensures that both roundworms and flukes are targeted simultaneously, thereby achieving superior and persistent worm control in livestock populations, a key differentiating factor in managing chronic parasitic burdens.

What side effects are possible with Cydectin TriclaMox?

Official Safety Profile and Adverse Reactions

The regulatory safety profile for Cydectin TriclaMox is defined by its high level of tolerance under normal conditions of use, with no adverse reactions known when the product is administered correctly to the target species. The information provided in official labeling focuses predominantly on the consequences of overexposure and strict limitations on use.

Signs of Intoxication (Overdose Only)

Adverse events are documented only in the context of significant overexposure, such as administration at three times the recommended dose. These transient signs of intoxication primarily affect the central nervous system and the animal's general condition, typically manifesting 8 to 12 hours post-treatment.

System-Organ Class	Signs Observed (Overdose)
Nervous System Disorders	Ataxia (loss of movement control)
General Disorders	Depression, Drowsiness, Transient Salivation
Gastrointestinal Disorders	Reduced food intake

Recovery from these signs is generally complete within one to five days. Official regulatory documents confirm that no specific antidote is available for these intoxication effects.

Population-Specific and Environmental Safety Restrictions

Specific contraindications must be observed as mandated by regulatory authorities:

Lambs: The product must not be used in lambs under 6 months of age or those weighing less than 20 kg.
Milk Production: It is not authorised for use in ewes producing milk for human consumption, including during the dry period, or in the 7-day period before lambing.
Concurrent Use: The medicine must not be used concurrently with any other endectocides or flukicides.

Due to Moxidectin's known aquatic toxicity, treated animals must be kept away from watercourses for the first 3 days after treatment, as required by environmental safety restrictions.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented overdose profile for Cydectin TriclaMox, based strictly on government regulatory documents.

Overdose manifestations are categorized as generally transient and self-limiting. The regulatory documents note that overdose signs have not been observed at several times the recommended dose. If an overdose occurs, the effects typically manifest 8 to 12 hours post-treatment.

Documented Overdose Presentation

The official labeling describes the following clinical signs associated with an overdose, consistent with the mode of action of the active ingredients:

Transient salivation
Depression
Drowsiness
Ataxia (incoordination)
Reduced food intake

Emergency Actions and Management

No specific antidote is known for Cydectin TriclaMox overdose.

Regulatory statements indicate that treatment is not generally necessary for the observed symptoms. Overdose effects are expected to resolve naturally, with recovery generally complete within 1 to 5 days.

Official guidance does not mandate immediate medical intervention or specialized supportive measures for the described transient signs. This regulatory guidance is based on the expectation of a self-limiting course and a favorable prognosis following the transient systemic and neurological changes.

Therapeutic Uses of Cydectin TriclaMox

Main Uses and Benefits of Cydectin TriclaMox

Cydectin TriclaMox is a combination anthelmintic solution designed for the treatment and control of mixed parasitic infections in livestock. By combining two distinct active ingredients, moxidectin and triclabendazole, the formulation addresses a broad spectrum of internal and external parasites simultaneously.

Targeted Parasites

The primary utility of this treatment lies in its ability to manage several types of parasitic burdens that affect animal health and productivity:

Liver Fluke: It is effective against all stages of the common liver fluke (Fasciola hepatica), including early immature, immature, and adult stages. This is particularly significant for preventing the damage caused by migrating flukes in the liver.
Gastrointestinal Roundworms: The solution targets various species of stomach and intestinal worms, including inhibited larvae, which can otherwise persist in the animal's system.
Lungworms: It provides control against adult and larval stages of lungworms, which are responsible for respiratory distress in affected animals.
External Parasites: The treatment also manages infestations of certain biting and sucking lice, as well as mange mites.

Benefits of Combination Therapy

Using a combination product offers several advantages for livestock management:

Comprehensive Control: Because it contains both a macrocyclic lactone and a flukicide, a single administration covers a wider range of parasites than single-active products.
Management Efficiency: Addressing both internal worms and liver flukes at various developmental stages reduces the need for multiple separate treatments, minimizing the frequency of animal handling.
Impact on Productivity: By reducing the parasitic burden, the treatment helps maintain the general condition of the animal, supporting normal growth rates and nutritional efficiency.

Regulatory References

UK VMD Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Profile and Restrictions

Cydectin TriclaMox is a veterinary medicinal product and its use is restricted exclusively to sheep. The official regulatory profile defines eligibility based on species, parasitic condition, and reproductive status related to the food chain.

Populations Contraindicated

Use is strictly contraindicated for all species other than sheep due to the risk of severe adverse reactions.
The product must not be used in ewes producing milk intended for human consumption, including during the dry period, nor within one year prior to the first lambing if intended for milk production.
It is contraindicated in any animal or human handler with a known hypersensitivity to Moxidectin, Triclabendazole, or the product's excipients.

Conditional and Restricted Use

The medicine should not be used for the treatment of single parasitic infections; it is reserved for sheep diagnosed with mixed nematode and fluke infections.
Pregnant ewes that are not producing milk for human consumption may be used.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cydectin TriclaMox (Moxidectin/Triclabendazole) is defined by the formal statement issued by government authorities regarding the absence of documented interactions. This section is structured exclusively on the information found in the official Summary of Product Characteristics (SmPC).

Regulatory Interaction Status

Regulatory documentation confirms the official status of interactions, stating that no interactions with other medicinal products or other forms of interaction are currently known or formally documented. This regulatory classification covers all major interaction types, ensuring a clear profile for co-administration.

Interaction Classification	Official Regulatory Status
Documented Drug–Drug Interactions	None known or documented
Formal Contraindicated Combinations	None specified or listed
Exposure-Altering Interactions	None known or documented
Timing-Based Separation Rules	None mandated or specified

Absence of Documented Interaction Constraints

The official label does not document any specific warnings or restrictions related to concurrent use with other substances. This means the regulatory profile does not contain:

Pharmacokinetic Interactions: No enzyme-mediated or transporter-based interactions that would alter the clearance or concentration of Moxidectin or Triclabendazole upon co-administration are listed.
Pharmacodynamic Interactions: No additive or synergistic effects with other specific medicinal products are documented in the regulatory text.
Interactions with Food or Supplements: The official label does not specify any interaction concerns with food, alcohol, or herbal products.

Mechanism of Action

How Cydectin TriclaMox Works

The pharmacological action of Cydectin TriclaMox is achieved through the independent and non-overlapping mechanisms of its two active components, achieving complementary action against nematodes and flukes.

Moxidectin: Neuromuscular Paralysis

Moxidectin acts as an agonist on glutamate-gated chloride channels (GluCl) in the roundworm's nerve and muscle cells. This targeted interaction triggers a massive influx of chloride ions, leading to hyperpolarization and the complete loss of nerve excitability. The mechanistic cascade results in the irreversible flaccid paralysis of the nematode's somatic and feeding musculature, leading to the cessation of all motor function.

Triclabendazole: Cytoskeletal and Metabolic Failure

Triclabendazole's active metabolites target the essential structural protein, beta-tubulin, within the fluke's cells. By inhibiting the polymerization of beta-tubulin, the drug prevents the formation of microtubules, which are crucial for cellular structure and internal transport. This disruption leads to a severe metabolic energy deficit and the collapse of the fluke's structural integrity, which results in the failure of the fluke's structure and metabolism across all life stages.

This combined dual-system approach is subject to molecular constraints, such as the efflux of Moxidectin by P-glycoprotein in some resistant nematodes or mutations in the fluke's beta-tubulin gene, which constrain the molecular interaction with the intended biological targets.

Dosage and Administration Information

How to Use Cydectin TriclaMox

This section describes the instructions for the administration and dosing of Cydectin TriclaMox Oral Solution.

Administration and Dosing

The medicine is designed strictly for oral use and is administered as a single oral drench. The dose volume must be calculated precisely based on the animal's weight, adhering to a weight-based dosing principle to ensure the correct amount of active ingredients is delivered.

Dosing Parameter	Instruction (Oral Solution)
Route of Administration	Oral (drench)
Volumetric Dose	1 ml per 5 kg body weight
Active Dose	Equivalent to 0.2 mg Moxidectin/kg and 10 mg Triclabendazole/kg
Frequency	Administered as a single oral drench

Procedural Administration Requirements

The correct use protocol requires specific procedural steps to be followed. Before treatment, the body weight must be determined as accurately as possible, and animals must be grouped according to their weight if treated collectively. Administration must utilize standard drenching equipment, and the accuracy of this device should be checked before starting the dosing process.

Furthermore, the protocol includes an environmental restriction tied directly to the use of the product: treated animals must be restricted from accessing watercourses for a period of 3 days following administration. This single-dose regimen is intended to provide persistent efficacy against specific re-infections for up to 35 days, with use strategies guided by local epidemiological data.

Recent Clinical Evidence

Research Evidence Overview

Evidence for Use in Mixed Nematode and Fluke Infections

Research examines conditions characterized by the simultaneous presence of two distinct parasite groups: roundworms (nematodes) and liver fluke (Fasciola hepatica). The evidence base includes controlled clinical trials using experimental infection and field studies observing animals with natural parasitic infections. Research also focused on activity against strains of parasites known to be resistant to older treatments (benzimidazole-resistant strains). Findings describe patterns observed in the reduction of parasite egg shedding and activity against various fluke life stages.

Outcomes Measured and Duration of Effect

Regulatory studies monitored two primary areas: parasite clearance and duration of anti-parasitic effect. Researchers evaluated the duration of the anti-parasitic measurements, with follow-up periods extending up to several weeks in intermediate-term trials. Beyond direct parasite measurements, studies also examined changes in production parameters related to health, such as live weight gain and wool yield.

Limitations and Subgroup Research

Research examined outcomes across various animal subgroups, including those with natural infections or resistant parasite strains. However, data for certain groups remain insufficient. A key limitation is that anti-parasitic activity measured in studies was observed to be influenced by geographic variation and reported resistance to the moxidectin and triclabendazole components. The regulatory assessment emphasizes that results apply only to the populations studied and that the use of findings is guided by local epidemiological data.

Key Studies & References Summary of Product Characteristics (SPC) for Cydectin TriclaMox Oral Solution – UK Veterinary Medicines Directorate (VMD)

Frequently Asked Questions (FAQ)

Common questions about Cydectin TriclaMox (FAQ)

Q: How long do the effects of Cydectin TriclaMox usually last?

A: Regulatory documents state that a single administration of Cydectin TriclaMox is indicated to provide persistent efficacy against specific re-infections of key roundworms for a duration of up to 35 days. The product’s activity against liver fluke is also assessed within the trials that support its use.

Q: How quickly does Cydectin TriclaMox start working?

A: The mechanism of action for the Moxidectin component is described as causing irreversible flaccid paralysis of the target parasites. The active ingredient reaches its maximum concentration in the bloodstream approximately 6 hours after administration.

Q: Are there certain foods or drinks that should be avoided when using Cydectin TriclaMox?

A: Official regulatory documents and the product label do not specify any known concerns or restrictions related to concurrent use with food, alcohol, or herbal products. The regulatory profile is clear that no such interactions are formally documented.

Q: Are the side effects of Cydectin TriclaMox permanent?

A: Adverse events are primarily documented only in cases of significant overexposure (overdose). Regulatory documents describe these transient signs of intoxication as temporary, with recovery generally described as complete within one to five days.

Q: What are the main findings from the research on Cydectin TriclaMox?

A: Regulatory-reviewed studies have focused on the product’s ability to treat mixed infections of roundworms and flukes. Findings examined patterns in the reduction of parasite egg shedding, activity against various fluke life stages was examined, and changes in health-related production parameters such as live weight gain.

Q: Is Cydectin TriclaMox the same as Cydectin?

A: No, Cydectin TriclaMox is a dual-active formula that combines Moxidectin with Triclabendazole to target two different types of parasites. In contrast, products typically marketed simply as 'Cydectin' contain Moxidectin alone.

Q: Can Cydectin TriclaMox be used alongside other common products?

A: Official regulatory texts state that no interactions with other medicinal products or other forms of interaction are currently known or formally documented. The product's regulatory profile suggests a clear interaction status.

Q: Does Cydectin TriclaMox interact with aspirin or common pain relievers?

A: Regulatory documents state that no interactions with other medicinal products, including non-specific products such as over-the-counter pain relievers, are currently known or documented. The official label does not specify any exposure-altering interactions.

Q: Why are people talking about Cydectin TriclaMox on certain online health forums?

A: The medicine is a dual-active anthelmintic combination that is recognized for its role in addressing complex parasitic resistance challenges. Its ability to treat both flukes and roundworms simultaneously may be a key topic discussed in professional and public forums.

Q: Does Cydectin TriclaMox require special preparation before use?

A: Procedural requirements include determining the animal’s body weight as accurately as possible and checking the accuracy of the standard drenching equipment before administration. The official documents do not list requirements for shaking or warming the oral solution itself.

Q: Is the 'Mox' component a common medicine name or unique to this drug?

A: The Moxidectin ('Mox') component is a recognized chemical entity classified as a semi-synthetic Macrocyclic Lactone. This indicates it belongs to a distinct and recognized class of anti-parasitic drugs.

Q: Can I stop using Cydectin TriclaMox if I feel better sooner?

A: The product is designed and administered as a single oral drench and is not intended to be part of a multi-day or multi-dose schedule.

Q: How important is it to follow the non-dosing instructions for Cydectin TriclaMox?

A: Following all procedural instructions is required. Official protocol includes critical environmental restrictions, such as limiting treated animals from accessing watercourses for a period of 3 days after treatment, due to the drug's known aquatic toxicity.

Q: Is Cydectin TriclaMox approved for use in all age groups?

A: The official regulatory profile restricts use in lambs under 6 months of age or those weighing less than 20 kg. Outside of these specified contraindications, the regulatory documents do not specify further age-related limitations for adult populations.

Q: What is the typical timeframe for a full course of Cydectin TriclaMox treatment?

A: The full course of treatment is defined by the administration of a single oral drench. This product is a one-time treatment and is not part of a recurring schedule.

Q: Can I find summaries of the clinical trials for Cydectin TriclaMox?

A: Yes, summaries of the studies and the detailed regulatory assessment can typically be found in the official public documents provided by government regulatory agencies. These include the European Medicines Agency (EMA) and the UK Veterinary Medicines Directorate (VMD).

Q: Is there research about Cydectin TriclaMox and reproductive health?

A: Official safety profiles and contraindication statements confirm that pregnant ewes not producing milk for human consumption may be treated. This indicates that regulatory research has addressed the use of the product in this reproductive population.

Q: Has Cydectin TriclaMox been approved in other major countries besides [Implied Country]?

A: Yes, the medicine holds regulatory approvals in multiple major territories. Regulatory documents are publicly available from bodies like the European Medicines Agency (EMA) and the UK Veterinary Medicines Directorate (VMD), indicating use across the EU and UK.

Q: Does the medicine come in different formulations or strengths?

A: Official documents describe the product as being available in different formulations. These include the Oral Solution used for sheep, as well as a Pour-on Solution which is typically authorized for other target species like cattle.

Q: What are the official recommendations if a user experiences an accidental overdose?

A: Official regulatory documents confirm that no specific antidote is available for the signs of intoxication (overdose). As the effects are transient, the animal’s recovery is generally complete within one to five days.

Q: What happens if I miss a scheduled application of the drug?

A: The product is administered as a single oral drench and is not intended to be part of a multi-day or multi-dose schedule where a dose could be missed.

How should Cydectin TriclaMox be stored and disposed of?

Storage and Disposal of Cydectin TriclaMox

Cydectin TriclaMox must be stored and handled according to specific regulatory requirements to maintain product stability and ensure environmental safety.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 25 °C; the product must not be frozen.
Light Protection	The container must be protected from light and kept in the outer carton.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The shelf-life for the unopened product is 2 years. Once opened, the solution has an in-use stability of 6 months.

Due to the active substance moxidectin being classified as a persistent, bioaccumulative, and toxic (PBT) substance, strict disposal mandates apply. Unused product and waste must be disposed of according to local regulatory requirements and must not enter water courses or be discharged into drains.

Cydectin TriclaMox